Don't miss this issue of The Altascientist
Shortening Drug Development Timelines with Asian Ethnobridging Trials
Developing drugs for the Asian market may require that Phase I studies be repeated in regions outside North America and Europe. Altasciences has the clinical capabilities to demonstrate biosimilarity of drug products between Asian and non-Asian populations by comparing pharmacokinetics of the investigational drug in both ethnic groups, providing a safe strategy to save time and money.
In our latest issue of The Altascientist, using case studies, we discuss how ethnobridging can prevent the necessity of regional-specific development programs, helping you achieve commercial milestones safely and more efficiently.
Speak with an expert today to discuss your next study!
Got a few more minutes? You may also be interested in the following webpages:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.